This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More
by Debanjana Dey
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.
Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform
by Zacks Equity Research
Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.
SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results
by Shaun Pruitt
After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.
Surmodics (SRDX) Q4 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust segmental revenues.
SurModics (SRDX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Snap These 4 Top-Ranked Liquid Stocks for Solid Returns
by Vaishali Doshi
Here are four top-performing liquid stocks, Deckers Outdoor (DECK), Surmodics (SRDX), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid returns.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Add These 4 Top-Ranked Liquid Stocks to Strengthen Portfolio
by Vaishali Doshi
Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and Sprinklr (CXM), which investors can add to their portfolio for solid gains.
Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.
Snap Up These 4 Top-Performing Liquid Stocks for Solid Gains
by Vaishali Doshi
Here are four top-ranked liquid stocks, Surmodics (SRDX), Fluor Corporation (FLR), NVIDIA (NVDA) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.
Why You Should Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Enrich Your Portfolio With These 4 Top-Ranked Liquid Stocks
by Vaishali Doshi
Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and NVIDIA (NVDA), which investors can add to their portfolio for solid gains.
Add These 4 Top-Performing Liquid Stocks for Strong Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.
Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.16% and 2.88%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 55.56% and 3.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) SurVeil DCB is indicated to treat percutaneous transluminal angioplasty in peripheral artery disease patients. Abbott will initiate commercialization of SurVeil DCB, per a deal with Surmodics.
Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?
by Zacks Equity Research
SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care
by Zacks Equity Research
Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.